中文名稱:布瓦西坦 | 英文名稱:Brivaracetam |
CAS:357336-20-0 | 純度規(guī)格: 98% |
產(chǎn)品類別: API |
Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program. It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract. Carcinogenicity studies are ongoing. Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability . CSD episodes were regularly elicited on slices upon delivery of calibrated KCl drops and were recorded via two micropipette electrodes. After control CSDs, the drug was added to the perfusion and five subsequent CSDs were elicited during drug perfusion. Effects were assessed via CSD amplitude (Ampl) and duration at half-amplitude (D(1/2)). BRV, 10 and 32 microM reduced the Ampl and transiently the D(1/2). Levetiracetam, 32 and 100 microM had no effect on either Ampl or D(1/2) . Brivaracetam bound selectively with 20 fold higher affinity than levetiracetam to SV2A . BRV produced a concentration-dependent inhibition of
成立日期 | 2013-06-21 (12年) | 注冊(cè)資本 | 2000000 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 500萬-1000萬 |
主營行業(yè) | 醫(yī)藥原料,醫(yī)藥中間體 | 經(jīng)營模式 | 貿(mào)易,工廠,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
上海潤泰醫(yī)藥科技有限公司
|
2024-12-30 | ||
¥800 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-30 | |
詢價(jià) |
VIP1年
|
湖北鴻福達(dá)生物科技有限公司
|
2024-12-30 | |
詢價(jià) |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2024-12-30 | |
詢價(jià) |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2024-12-30 | |
詢價(jià) |
VIP9年
|
滄州恩科醫(yī)藥科技有限公司
|
2024-12-30 | |
詢價(jià) |
VIP9年
|
湖北威德利化學(xué)科技有限公司
|
2024-12-30 | |
詢價(jià) |
VIP5年
|
深圳菲斯生物科技有限公司
|
2024-12-30 | |
詢價(jià) |
VIP10年
|
樺特昇生物科技(武漢)有限公司
|
2024-12-30 | |
¥400 |
VIP12年
|
湖北威德利化學(xué)科技有限公司
|
2024-12-30 |